key: cord-0933557-1b7l7dgf
authors: Abayasingam, Arunasingam; Balachandran, Harikrishnan; Agapiou, David; Hammoud, Mohamed; Rodrigo, Chaturaka; Keoshkerian, Elizabeth; Li, Hui; Brasher, Nicholas A.; Christ, Daniel; Rouet, Romain; Burnet, Deborah; Grubor-Bauk, Branka; Rawlinson, William; Turville, Stuart; Aggarwal, Anupriya; Stella, Alberto Ospina; Fichter, Christina; Brilot, Fabienne; Mina, Michael; Post, Jeffrey J.; Hudson, Bernard; Gilroy, Nicky; Dwyer, Dominic; Sasson, Sarah C.; Tea, Fiona; Pilli, Deepti; Kelleher, Anthony; Tedla, Nicodemus; Lloyd, Andrew R.; Martinello, Marianne; Bull, Rowena A.
title: Long-term persistence of RBD-positive memory B cells encoding neutralising antibodies in SARS-CoV-2 infection
date: 2021-03-14
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100228
sha: f3743a9c04eed9c728d88d5aa134daa056e39372
doc_id: 933557
cord_uid: 1b7l7dgf

Considerable concerns relating to the duration of protective immunity against SARS-CoV-2 exist, with evidence of antibody titres declining rapidly after infection and reports of reinfection. Here we monitor the antibody responses against SARS-CoV-2 receptor binding domain (RBD) for up to six months after infection. While antibody titres are maintained, about 13% of the cohort’s neutralising responses return to background. However, encouragingly in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralising capacity from these memory B cells. Overall our study suggests that the loss of neutralising antibodies in plasma may be countered by the maintenance of neutralising capacity in the memory B cell repertoire.

Virus and host immune factors impact on the severity of acute infection, and the 2 subsequent quality and durability of immunological memory that will be established to 3 protect against reinfection. 1 In SARS-CoV-2 infection, at least 80% of people infected 4 appear to have asymptomatic or mild disease, while the remaining 20% are more 5 severely unwell, with hyperactivation of the immune system leading to excessive 6 production of pro-inflammatory cytokines, lymphopenia, development of acute lung 7 injury, and other end organ damage. [2] [3] [4] Age and disease severity have been linked with 8 higher antibody titres and virus-specific neutralising activity, 5 and it has been suggested 9 that antibody responses may wane more quickly following mild illness, 6 although not 10 all studies support these observations. 7,8

As the COVID-19 pandemic continues to spread, the development of a prophylactic 12 vaccine is critical. 9 A key component underpinning a successful vaccine design is an In SARS-CoV-1 infection, the maintenance of durable NAb responses is unclear. Older 3 studies suggest the initial specific IgG and NAb titres fall progressively over 2-3 years 4 to become undetectable in up to 25% of individuals, 17 and a recent study demonstrated 5 that low titre SARS-CoV-1 NAbs were still detected in half of the group tested 17 years 6 afterwards 18 . Short-lived or low-titre NAb responses may not be a problem if robust 7 memory B cell responses are generated and can be re-activated upon reinfection. 8 However, memory B cell responses in SARS-CoV-1 may also be short-lived 11 . To date, 9 only two studies have examined the SARS-CoV-2-specific memory B cell response 10 beyond four months. 19, 20 Encouragingly, both these studies report that SARS-CoV-2- At t1, 78 of 81 participants (96%) had RBD EPTs greater than the limit of detection 17 ( Fig 1A) . In addition, two of the three non-reactive participants did not have antibodies 18 against the Spike protein ( Fig S1A) . For neutralisation activity with the pseudovirus 19 assay, 54 of 81 participants (67%) had an ID50 above cut-off (Fig 1B) . At t2, the 20 average ID50 and EPT values were significantly lower compared to t1 [mean difference 21 (SEM) -ID50: 37.3 (14.0), p=0.009, EPT: 885 (258.4), p=0.001), but 95% (77/81) and 22 74% (60/81) of participants had EPT and neutralisation activity above the defined cut-23 offs (Fig S1B,C) .

To validate the percentage of subjects that had undetectable levels of neutralisation 25 activity, ID50s were also calculated with a live virus assay. The ID50 cutoff defined by 26 J o u r n a l P r e -p r o o f the 19 healthy controls for the live virus was 0.6 (0.06 + 2 x 0.27). The live virus and 1 pseudovirus data correlated (r=0.65) (Fig. S1G ) and a similar trend in decline was 2 observed between t1 and t2 (Fig 1C) . At t1 86.4% (70 of 81) of participants and at t2 3 86.4% (70 of 81) participants remained above the threshold for detectable neutralising 4 activity. Of these 11 participants at t1, seven were below the threshold again at t2. For 5 both neutralisation assays, there were many participants that were only just above the 6 threshold for neutralising activity (Fig. 1B, 1C (Table S1 ). In the adjusted analysis (metabolic comorbidity vs. 16 paired EPT measurements with sampling gap and age as covariates), the association 17 with metabolic comorbidities disappeared while that for age and EPT was borderline 18 (p=0.05) (Table S2 ). Paired ID50 values did not have a significant association with any 19 of the demographic or clinical variables assessed in the unadjusted analysis (Table S3) .

There were also no significant associations between demographic and clinical variables 21 and fold-change in EPT or ID50 (t2 value/t1value), except that a longer time between 22 sample collection was associated with a greater fold decline of EPT and ID50 (p<0.05). The observed decline in neutralising activity could be mitigated if a durable memory B 1 cell response capable of generating neutralising antibodies on demand is maintained. In 2 order to assess the presence of a RBD-specific memory B cell response, 15 participants 3 representing high (>1000 EPT, n=5), medium (EPT:100-999, n=7) and low EPT 4 (EPT<100, n=3) at t1 were selected, and their t1 and t2 PBMCs were screened for 5 RBD-specific CD27+ memory B cells by flow cytometry. The 15 participants were 6 generally representative of the broader study cohort, in relation to gender (female=7), 7 disease severity (mild=4, moderate=7, severe= 4) and age (range 23 to 84). Six healthy 8 uninfected participants were included as negative controls. CD27+RBD+IgD-IgG-(52.3 ± 72.7/10 6 B cells) (Fig 2B) . Despite some inter-subject 26 J o u r n a l P r e -p r o o f variation, 12 out of 15 participants had a CD27+RBD+IgD-IgG+ frequency above the 1 healthy control derived cut-off at t2, and this was a significant increase from the same 2 values observed at t1 (mean t1= 165.8/10 6 B cells; mean t2=336.9/10 6 B cells p=0.0084) 3 ( Fig 2C) . Two participants who did not have a CD27+RBD+IgD-IgG+ B cell responses 4 greater than the healthy cut-off were from the low EPT group, and had mild or moderate 5 clinical illnesses; the third was from the high EPT group and had severe disease. There 6 was overall a strong correlation between IgG EPT and CD27+RBD+IgD-IgG+ B cell 7 frequencies (r=0.613, p-value=0.017) at t2 (Fig 2D) . No correlation between ID50, (Table 2) . For this analysis, we selected three 15 timepoints that had low to no detectable EPT and pseudovirus ID50 and three time 16 points that had well above healthy cut-off titres. For participants that had a low IgG+ 17 cell frequency, IgD+ cells were used (Table 2) 

A neutralisation percentage greater than 40 was defined as having neutralising activity.

Of the 50 mAbs that bound RBD, 14 mAbs from three of the five participants had 24 neutralising activity (Table 2) ( Fig 2F) . To further confirm the neutralising activity, the 25 IC50 was determined for the two highest NAbs from each of the three participants by 26 J o u r n a l P r e -p r o o f quantifying the mAbs in the cell culture supernatant and performing neutralisation 1 assays on the SARS-CoV-2 pseudovirus ( Fig 2G) . No neutralising antibodies were 2 isolated from the two patients that did not seroconvert. Sequence analysis of these six 3 potent mAbs revealed they were a mix of IGHV genes and had undergone affinity 4 maturation as indicated by a somatic hypermutation level of 2-7%. Our observation is that despite declining EPT and ID50 values at four to six months 10 following infection, most individuals retain binding and neutralisation titres above 11 background. Gender, disease severity, immunosuppression, comorbidities (diabetes 12 mellitus, hypertension, obesity), and a past or current history of smoking, did not 13 predict variation in ID50 or EPT over time.

14 15 A decline in antibody titres and neutralising capacity following resolution of the clinical 16 illness is not unusual, as seen in several other viral infections. However, the observation 17 of antibody titres dipping below a detectable level is a concern for ongoing protection.

Comparable declines in antibody titres would also be a significant concern following 19 COVID-19 immunisation, if and when a vaccine is available 20 . Even though a potential 20 vaccine against SARS-CoV-2 may not confer sterilising immunity (as this is rarely 21 observed in other vaccines approved for use), the capacity of such a vaccine to minimise 22 disease, reduce viral shedding and thence reduce transmission remains a highly 23 desirable public health measure to control the pandemic. Our study also identified a correlation between the frequency of RBD-specific memory 1 B cells and RBD EPT, which indicates that RBD EPT may be a good and readily 2 available marker for potential immunity. It is noteworthy, however, that the subject with 3 the highest NAb titres had IgG RBD-specific memory B cells at background level only. The limited number of participants in this study did not allow for an expanded robust 20 analysis of different co-morbidities, age or treatment on antibody and memory B cell 21 dynamics, instead this study only focused on a subset grouped as metabolic disease. were included in this study and had a median age of 51 years (IQR: 34 -63.5 years) and 2 51% were female (n=41) ( Table 1) .

Follow up visits were scheduled at one month (visit window: one to three months) and 5 four months (visit window: four to six months) following symptom onset or date of 6 diagnosis (whichever was first). At each follow up visit, clinical data and blood samples 7 were collected. Disease severity was classified according to the NIH stratification 8 (www.covid19treatmentguidelines.nih.gov). All 293T human embryonic kidney cells and Vero E6 cell were maintained at 37°C, 5% CO2 5 and >90% relative humidity in growth medium containing high glucose Dulbecco's Modified 6

Eagle Medium (ThermoFisher Scientific) supplemented with 10% v/v heat inactivated fetal 7 bovine serum (Life Technologies; ThermoFisher Scientific). Expi293-Freestyle cells 8 (ThermoFisher Scientific) were cultured at 37°C and 8% CO 2 in growth medium containing 9

Expi293 Expression Medium (ThermoFisher Scientific). 10

Primary PBMCs were cryopreserved RPMI media supplemented with 2 mM L-glutamine, supplemented with 2 mM L-glutamine, and 10% heat inactivated fetal calf serum 6 (Sigma). Cells were incubated at 37°C and 5% CO 2 for 6-8 hours before media was 7 replaced with 3 mL of DMEM supplemented with 2% heat inactivated fetal calf serum 8 and 1% penicillin/streptomycin, and incubated under the same conditions for a further 9 67-72 hours. Media was then collected and centrifuged to isolate supernatant containing 10 antibodies, before storage at -20°C.

A RBD binding ELISA was performed on the undiluted mAbs, as described above for 12 serum, to determine the specificity of the RBD tetramer-sorted memory B cells. Table S1 Primers for backbone (C, H, ĸ and λ) fragment cloning PCR, see Table S1 Primers for varable (V H , V ĸ and V λ ) fragment PCR, see Table S1 Primers for expression cassette assemble overlapping PCR, see Inclusion and diversity 9 We worked to ensure gender balance in the recruitment of human subjects. We worked 10 to ensure that the study questionnaires were prepared in an inclusive way. One or more 11 of the authors of this paper self-identifies as an underrepresented ethnic minority in 12 science. One or more of the authors of this paper self-identifies as a member of the 13 LGBTQ+ community. The author list of this paper includes contributors from the 14 location where the research was conducted who participated in the data collection, 15 design, analysis, and/or interpretation of the work. 

Viral escape mechanisms--2 escapology taught by viruses

Clinical features of patients infected with 2019 novel coronavirus in 4

T-cell subset counts in peripheral blood can be used as 6 discriminatory biomarkers for diagnosis and severity prediction of Coronavirus 7 disease 2019

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in

SEROCoV-POP): a population-based study

Longitudinal evaluation and decline of antibody responses in SARS-12 CoV-2 infection

Antibody responses to SARS-CoV-2 in patients with COVID-19

Antigen-Specific Adaptive Immunity to SARS-16

CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Orthogonal SARS-CoV-2 Serological Assays Enable 19 Surveillance of Low Prevalence Communities and Reveal Durable Humoral 20

A Snapshot of the Global Race for Vaccines 22

CoV-2 and the COVID-19 Pandemic

SARS-CoV-2-reactive interferon-γ-producing CD8+ T cells in 25 patients hospitalized with coronavirus disease 2019

Immunology of COVID-19: current state of the science

Breadth of concomitant immune responses prior to patient 31 recovery: a case report of non-severe COVID-19

A systematic review of antibody mediated immunity to 33 coronaviruses: antibody kinetics, correlates of protection, and association of 34 antibody responses with severity of disease

Spread of SARS-CoV-2 in the Icelandic Population

High prevalence of SARS-CoV-2 antibodies in care homes 38 affected by COVID-19

Cross-sectional evaluation of humoral responses against SARS-40

Disappearance of 42 antibodies to SARS-associated coronavirus after recovery

A SARS-CoV-2 surrogate virus neutralization test based on 45 antibody-mediated blockage of ACE2-spike protein-protein interaction

SARS-CoV-2 specific memory B cells frequency in 48 recovered patient remains stable while antibodies decay over time

Evolution of immunity to SARS-CoV-2. medRxiv

Single-shot Ad26 vaccine protects against SARS-CoV-2 in 53 rhesus macaques

REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 1 infection in rhesus macaques and hamsters

Asymptomatic reinfection in two healthcare workers from India 3 with genetically distinct SARS-CoV-2

Functional SARS-CoV-2-specific immune memory persists after 6 mild COVID-19. medRxiv

Lack of peripheral memory B cell responses in recovered patients 8 with severe acute respiratory syndrome: a six-year follow-up study

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal 11 Centers in COVID-19

Characterization of the human myelin oligodendrocyte glycoprotein 14 antibody response in demyelination

Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Mutations in hepatitis C virus E2 located outside the CD81 binding 20 sites lead to escape from broadly neutralizing antibodies but compromise virus 21 infectivity

In vitro assay for neutralizing antibody to hepatitis C virus: 23 evidence for broadly conserved neutralization epitopes

Optimised cell systems for the investigation of hepatitis C 26 virus E1E2 glycoproteins. bioRxiv

Protocol and Reagents for Pseudotyping Lentiviral 29 Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Revising a display of multidimensional laboratory measurements to 32 improve accuracy of perception

A method for detecting hepatitis C envelope specific memory B cells 34 from multiple genotypes using cocktail E2 tetramers

B-cell receptor reconstruction from single-cell RNA-seq with 37

High-throughput isolation of immunoglobulin genes from single 40 human B cells and expression as monoclonal antibodies

Change-O: a toolkit for analyzing large-scale B cell 43 immunoglobulin repertoire sequencing data

The authors would like to thank the study participants for their contribution to the 22 research, as well as current and past researchers and staff. They would like to